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analysis including: acute GVHD, conditioning regimen, marrow
vs. PBSC; related vs. unrelated donor, matched vs. mismatched
donor, recipient age and time post-HCT was performed Table 1.
cGVHD patients had a profile consistent with T effector cell ac-
tivation that was not present in TOL.
The characteristic inflammatory environment, increased cytokine
production, immunosuppressive therapy and impaired T cell im-
mune reconstitution observed in cGVHD, may increase the risk of
CMV reactivation and subsequent upregulation of genes related to
T cell activation and effector functions. In contrast, tolerant patients
may have achieved greater immune reconstitution andmore effective
CMV surveillance and control.
T cell activation during cGVHD is a complex process that appears
to be influenced by latent CMV.
Table 1. Multivariate analysis
Active cGVHD TolerantCMV+ (n 5 17) vs
CMV-(n 5 21)CMV+ (n 5 11) vs
CMV-(n 5 19)ITK 0.023[
CD86 0.034[
PLCG1 0.033[
PIK3CB 0.005[
GZMB 0.024[
INFg 0.015[
IL4R 0.025YPTPN7 0.000[
PRF1 0.000[
GZMA 0.003[
PDCD1 0.008[
IL12RB1a 0.016[
IL12RB1b 0.000[Ydownregulated gene
[upregulated gene454
INDUCTION OF A GVHD-LIKE SYNDROME FOLLOWING ALLOGENEIC
BMT AND CsA THERAPY
Bryson, J.S.1,3,4, Brandon, J.A.3,4, Jennings, C.D.2,4, Kaplan, A.M.3,4
1University of Kentucky, Lexington, KY; 2University of Kentucky, Lex-
ington, KY; 3University of Kentucky, Lexington, KY; 4University of Ken-
tucky, Lexington, KY
Cyclosporine A (CsA) is a calcineurin inhibitor that is used to pre-
vent graft-versus-host disease (GVHD) following allogeneic hema-
topoietic stem cell (HSCT)/bone marrow transplantation (BMT).
While CsA is utilized for the prophylaxis of GVHD, many patients
develop GVHD while on, or after removal from therapy. A disorder
develops with clinical symptoms and pathology that is similar to al-
logeneicGVHDafter syngeneic BMTandCsA therapy and has been
termed, syngeneic GVHD (SGVHD). In mice, SGVHD is mediated
by CD4+ T cells and required an intact host microbiota for the dis-
ease to develop. Interestingly, it was recently shown that antibiotic-
responsive intestinal inflammation developed after cord blood stem
transplantation and treatment with calcineurin inhibitors as prophy-
laxis for the development of GVHD. Data will be presented that
demonstrates the induction of a GVHD-like disease following allo-
geneic BMT and CsA therapy in mice. We have termed this disease
CsA-induced pseudoGVHD (PGVHD). In this inducible disease,
pathology characteristic of GVHD occurs in the colon and liver.
Similar to the SGVHDmodel, increasedCD4+T cell responsiveness
against microbial antigens is associated with an increase in TH1/
TH17 immunity relative to control BMTanimals. Themechanism(s)
responsible for the induction of PGVHDare unknown.Whether the
development of this disorder is due to incomplete immunosuppres-
sion, altered immune regulation, generation of immunity against mi-
crobial antigens or a combination of these possibilities is currently
under investigation. The PGVHD model will shed light on thisquestion with an eye towards future development of novel therapies
to address this issue clinically.455
SYSTEMIC EFFECTS OF ORAL BUDESONIDE IN HEMATOPOIETIC TRANS-
PLANT: IMPLICATIONS OF DRUG INTERACTION WITH AZOLES
Obi, G.A.1, Fakih, R.E.L.2, Scholoff, A.1, Carrum, G.1, Kamble, R.T.1
1Baylor College of Medicine and the Methodist Hospital, Houston, TX;
2Baylor College of Medicine, Houston, TX
Oral budenoside (BUD) is commonly used as a topical adjunct in
graft-versus-host-disease (GVHD) of the gastrointestinal tract.
BUD possesses a high ratio of topical-to-systemic activity that limits
steroid toxicity. It is, however, inactivated via cytochrome P450 iso-
enzymes so that concomitant administration of azoles which com-
pete for this enzyme increases its bioavailability. The clinical
significance of such increased bioavailability after hematopoietic
stem cell transplantation is unknown.
The development of iatrogenic Cushing’s syndrome in a patient
receiving allogeneic hemopoietic stem cell transplantation (al-
loHSCT) who was taking BUD as the sole source of steroids, led
us to explore the frequency of Cushing’s disease or other manifesta-
tions of significant systemic exposure to exogenous steroids in pa-
tients who had received alloHSCT and were receiving both BUD
and an azole drug.We reviewed the medical charts of the 60 patients
who received an alloHSCT between January 2008 and August 2011.
Five patients (Table-1) met the criteria of diagnosis of acute or
chronic GVHD; continuation of BUD for a further 21 days or
more after cessation of systemic steroids; and concomitant adminis-
tration of an azole drug. The charts were reviewed for evidence of
clinical development of iatrogenic Cushing’s syndrome and for evi-
dence of abnormalities in morning plasma cortisol levels and serum
glucose levels.
BUD was initiated at 9 mg per day and the dose was titrated ac-
cording to response. All these patients were receiving either flucona-
zole (n 5 3) or voriconazole (n 5 2) for fungal prophylaxis.All had
suppression of morning plasma cortisol consistent with systemic ab-
sorbtion and significant plasma levels of the topically applied drug.
The patients also had rapid (within 3 weeks) onset of iatrogenic
Cushing’s syndrome, with median weight gain of 5.7 kg (range 5
4-7.1 kg). All patients developed facial mooning, central obesity
and glucose intolerance. Plasma cortisol remained at 1 ug/dl even
when BUD was titrated to 3mg/day, at which time exacerbation of
GUT and/or skin GvHD was seen, necessitating dose escalation.
Absolute neutrophil and lymphocyte counts remained unchanged
with no increased infections.
Hence the effect of combining azole-drugs with BUD is to consis-
tently increase systemic levels of the steroid sufficiently to induce
Cushing’s syndrome, reducing the selective benefit of this ‘‘topical’’
agent for gut GvHD in patients receiving both agents.
Table 1. Patients characteristics on BUD alone
GVHD/ BUD alone Cushing’sPatient/transplant Treatment duration (days) manifestation52, M, AML,
MIUD in CR-2,
BU/CY/AL,
tacrolimus
Grade II aGvHD,
skin, gut, liver,
Limited cGvHD,
skin, gut,
Prednisone,
BUD571* Plasma
cortisol 5 1 ug/dl,
weight gain 5 5.7 kg,
facial mooning,
central obesity,
glucose intolerance51, M, AML,
MRD in active
disease, BU/CY,
MTX,
tacrolimus
Grade II aGvHD,
skin,gut,
prednisone,
BUD62 Plasma cortisol 5 1ug/dl,
weight gain 5 4 kg facial
mooning, central obesity,
glucose intolerance67, M, AML,
MUD in CR-2,
FL/MEL/AL,
tacrolimus
Grade II aGvHD,
skin, gut,
Limited cGvHD,
skin, gut,
prednisone,
BUD151* Plasma Cortisol 5 1ug/dl,
weight gain 5 4.7 kg,
facial mooning, glucose
intolerance(Continued )
S372 Poster Session IITable 1. (Continued )Patient/transplantGVHD/
Treatment dBUD alone
uration (days)Cushing’s
manifestation54, M, AML,
MUD in CR1,
FL/MEL/AL,
tacrolimus
Grade III GvHD,
skin, gut, liver,
Limited cGvHD,
skin, prednisone,
infliximab, rituximab,
BUD40* Plasma cortisol 5 1ug/dl,
weight gain 5 7.1kg,
worssening of existing
central obesity, facial
mooning and glucose
intolerance57, M, AML,
MRD in active
disease, BU/CY,
MTX,
tacrolimus
Grade II aGvHD,
skin, gut, liver,
Limited cGvHD,
liver, skin256 Plasma cortisol 5 1ug/dl,
weight gain 5 6.7 kg,
central obesity, mood
changes, facial mooning,
glucose intoleranceM indicates male; AML, acute myelogenous leukemia; MIUD, mis-
matched unrelated donor; CR, complete remission; BU, busulfan; CY,
cyclophosphamide; AL, alemtuzumab; Cd, cluster differentiation;
aGvHD, acute-graft-versus-host disease; cGvHD, chronic graft-versus-
host disease; BUD, budenoside; Kg, kilogram; MRD, matched related
donor
*Continued BUD456
AN IMMUNOLOGICAL ASSESSMENT OF B AND T CELLS IN PATIENTS
WITH CHRONIC GRAFT VS HOST DISEASE UNDERGOING EXTRACORPO-
RAL PHOTOPHERESIS (ECP)
Dalal, J.1, Ashraf, H.2, Yankee, T.2, McGuirk, J.2, Abhyankar, S.2
1Children’s Mercy Hospital, Kansas City, MO; 2University of Kansas
Medical Center, Kansas City, KS
ECP is well established in the treatment of cGvHD.The mecha-
nism of ECP is unknown, but improvement in the patients has
been correlated with a rise in theT-reg numbers in some studies. Re-
cently the role of B cells in cGvHD has also been reported by Grei-
nex et al. In this study we analyzed the B and T cell numbers and
function in patients undergoing ECP for cGvHD.The study was ap-
proved by the IRB and informed consent obtained. Patients with
cGvHD who had failed prior therapy with steroids or were steroid
dependent or intolerant were enrolled. ECP was performed for
two consecutive days per week for the first 4 weeks and then de-
creased to two treatments every two weeks for the next 12 - 14 weeks.
At that point, if the GvHD was stable or improved, the same fre-
quency of ECPwas continued until 6 months. If there was no impro-
vemen, then the patient was taken off the ECP study.
Comprehensive cGvHD assessments were done by NIH consensus
criteria, at baseline, and then every 2 months for 6 months.These in-
cluded pulmonary function testing, ophthalmology testing, and clin-
ical grading. Blood was taken from the patient from the peripheral
vein as well as from the mononuclear collection from the ECP ma-
chine, prior to the photo-activation. All ECP treatments were
done on the Therakos Celex system. The blood and the mononu-
clear cells were analyzed for T and B cell subset by flow cytometry
for Naive T cells, Central Memory T cells, Effector Memory T cells
and recent thymic emigrants.Plasma was collected and analyzed for
cytokine profile forTh1 andTh2 cytokines. Subsequently themono-
nuclear were cultured and stimulated with anti-CD3 and CD28 an-
tibodies and the cytokine profile will be analyzed. Ten patients havebeen enrolled in the study. All patients are continuing on the ECP
treatment and no patient had to stop the ECP. Patients were on
prednisone and other immunosuppressants at the time of ECP com-
mencement. Data is available on 6 of the 10 patients. ECP therapy
elevated the percentage of CD4 cells that were Tregs. For two pa-
tients, this elevation was not sustained when the frequency of treat-
ment was reduced. The reduction of Tregs in the two patients
correlated perfectly with a reduction in PFT performance. 4/6 pa-
tients saw sustained Treg elevation and no reduction in PFT. B
cell subset analysis showed downward trend in IgD+ memory cells.
These preliminary results show the role of B and T cell in ECP
treated patients and may serve as markers for monitoring response.457
LIMITED BENEFIT OF PENTOSTATIN SALVAGE THERAPY FOR STEROID
REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
Alam, N., Viswabandya, A., How, J., Gupta, V., Kim, D., Lipton, J.,
Messner, H., Kuruvilla, J. Princess Margaret Hospital, University of Tor-
onto, Toronto, ON, Canada
Corticosteroid refractory (steroid REF) acute graft versus host
disease (A-GVHD) remains one of the major causes of morbidity
and mortality in patients undergoing allogeneic stem cell transplan-
tation (allo-SCT).Multiple agents have been evaluated in this setting
including the purine analog pentostatin but the benefit of adding
pentostatin to ongoing treatment is not well described. We report
a single center experience of pentostatin salvage therapy for steroid
REF A-GVHD. 15 patients received pentostatin as additional treat-
ment of ongoing steroid REF A-GVHD at PMH from Mar 2005-
Mar 2010. Median age was 38 years (Range 21-69). Stem cell source
was PBSC 100%. Matched related donor transplants were per-
formed in 9(60%); 6(40%) underwent unrelated donor transplants.
Conditioning was MA in 11(73%) patients and RIC in 4(27%).
GVHD prophylaxis was cyclosporine in combination with metho-
trexate (n 5 8), MMF (n 5 5), or alemtuzumab (n 5 2). Median
day of development of A-GVHD was 28 days (range 10-56). All pa-
tients had grade III-IVA-GVHD.Thirteen (87%), ten (67%) and six
(40%) patients had GI, skin and liver involvement, respectively. All
patients received steroids as first line treatment. Most patients re-
ceived 1 mg/kg as initial dose but went on to 2 mg/kg on third to
fourth day if no response. Patients who did not respond to methyl-
prednisolone $ 2mg/kg/day for at least 7 days were considered ste-
roid refractory. Eleven (73%) of these patients receive pentostatin as
first line therapy after being deemed steroid refractory. Pentostatin
(1.4 mg/m2 IV) was administered at the median of 53 days after
HSCT (Range 22-240). 10(66%) patients received all 3 doses. Ten
(66%) also received other therapies including mesenchymal stromal
cell investigational product or placebo (n5 5, 33%) at the same time
as part of Osiris study. Other therapies included tacrolimus (n 5 3),
infliximab (n 5 1), MMF (n 5 1), Sirolimus(n 5 1), ATG (n 5 1),
cyclophosphamide(n 5 1). Published criteria from McMillan et al
were used for response assessment. 2 complete responses were seen
(both in skin) but one patient relapsed and did not respond to second
treatment. 3 patients demonstrated PR. 3 out of 5 patients who re-
sponded were involved in Osiris study also. Fourteen died of
GVHD related causes (GI bleed (n 5 1), infections (n 5 5), hepatic
failure (n5 4) and hepatorenal syndrome (n5 4)). One patient is still
alive at last follow up. Pentostatin is of limited benefit in the treat-
ment of steroid refractory acute GVHD.
